News

Two years of treatment with Nucala (mepolizumab) safely and effectively reduces signs and symptoms of hard-to-treat eosinophilic granulomatosis with polyangiitis (EGPA), the rarest form of ANCA-associated vasculitis. That’s according to a real-world study in Italy that also found similar outcomes with benralizumab, a therapy that works similarly to…

The prognostic immune nutritional index or PINI — a novel clinical tool based on counts of immune cells and levels of a blood protein called albumin — can be used to help predict the risk of death in people with ANCA-associated vasculitis (AAV), a new study shows. For serious…

Microscopic polyangiitis (MPA) was the most common type of ANCA-associated vasculitis (AAV) among girls and Hispanic children in a California tertiary care hospital, a small study has found. While time to diagnosis was shorter, children with the disorder seemed to need more intensive care and dialysis, a treatment that…

A rare case of two family members with granulomatosis with polyangiitis (GPA), a type of ANCA-associated vasculitis (AAV), highlights the potential genetic underpinnings of the autoimmune disease, according to a recent report. This case of a mother and son both presenting with GPA add to a small, but accumulating,…

An approach that removes specific antibodies from a person’s blood is better than a standard, more general blood-cleaning procedure called plasma exchange at clearing the self-reactive antibodies that drive ANCA-associated vasculitis (AAV). That’s according to a small study in China that looked at data from AAV patients with severe…

People with ANCA-associated vasculitis (AAV) often face a high medication burden — managing multiple medications, also known as polypharmacy — with most patients covered by Medicare on five or more treatments at the same time in the first year after their diagnosis, a study found. Among the factors…

Blood levels of globulins — a group of proteins that includes antibodies — when ANCA-associated vasculitis (AAV) is diagnosed can help in forecasting the risk of a patient dying of any cause, a large data study from Korea suggests. “The present study is the first to demonstrate that [total…

Rates of preterm delivery, lower-than-normal birth weight, and maternal disease flares are higher among pregnant women with ANCA-associated vasculitis (AAV) than in the general population, according to a review study. Despite this, “most pregnancies resulted in healthy newborns and manageable, non-life-threatening flares of AAV,” the researchers wrote, suggesting that “pregnancy…

Treatment with Tavneos (avacopan) results in significant and clinically meaningful improvements in health-related quality of life (HRQoL) for people with ANCA-associated vasculitis (AAV), according to findings from the Phase 3 ADVOCATE clinical trial. “The ADVOCATE study is, to our knowledge, the first trial in patients with ANCA-associated vasculitis…

Dosing has begun in a Phase 2 clinical trial of imlifidase, an  antibody-cleaving therapy, in people with ANCA-associated vasculitis (AAV) who have or are at risk of disease-associated acute respiratory distress syndrome (ARDS), Hansa Biopharma, the therapy’s developer, announced. ARDS, a severe complication of AAV, occurs…